Literature DB >> 16311405

Treatment of pituitary tumors: history.

Gaya Thanabalasingham1, Niki Karavitaki, Simon Cudlip, John A H Wass.   

Abstract

Over the past century our understanding of the pituitary disease has undergone an amazing evolution, accompanied by impressive advances in the therapeutic approaches to pituitary tumors. This historical review aims to provide insights into the contributions of key medical and scientific pioneers, their occasionally serendipitous discoveries, and the lively global debates, which have ultimately improved the therapeutic targets and the long-term outcome of these patients. The development of the three main modalities is discussed (surgery, irradiation, pharmacotherapy). More recent experimental data, which may provide a path to a stronger therapeutic armamentarium for these undoubtedly challenging tumors, are also briefly reported.

Entities:  

Mesh:

Year:  2005        PMID: 16311405     DOI: 10.1385/ENDO:28:1:003

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  47 in total

1.  Rational design of potent antagonists to the human growth hormone receptor.

Authors:  G Fuh; B C Cunningham; R Fukunaga; S Nagata; D V Goeddel; J A Wells
Journal:  Science       Date:  1992-06-19       Impact factor: 47.728

2.  The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

Authors:  Leo J Hofland; Joost van der Hoek; Richard Feelders; Maarten O van Aken; Peter M van Koetsveld; Marlijn Waaijers; Diana Sprij-Mooij; Christian Bruns; Gisbert Weckbecker; Wouter W de Herder; Albert Beckers; Steven W J Lamberts
Journal:  Eur J Endocrinol       Date:  2005-04       Impact factor: 6.664

3.  III. Partial Hypophysectomy for Acromegaly: With Remarks on the Function of the Hypophysis.

Authors:  H Cushing
Journal:  Ann Surg       Date:  1909-12       Impact factor: 12.969

Review 4.  Endocrine profile of ergot alkaloids.

Authors:  E E Můller; A E Panerai; D Cocchi; P Mantegazza
Journal:  Life Sci       Date:  1977-12-01       Impact factor: 5.037

5.  Stereotaxic radiofrequency surgery of the normal and the abnormal pituitary gland.

Authors:  N T Zervas
Journal:  N Engl J Med       Date:  1969-02-20       Impact factor: 91.245

Review 6.  Octreotide.

Authors:  S W Lamberts; A J van der Lely; W W de Herder; L J Hofland
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

7.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Authors:  A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

8.  Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.

Authors:  G Plewe; J Beyer; U Krause; M Neufeld; E del Pozo
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

Review 9.  Dopamine resistance of prolactinomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

10.  A pituitary parasellar tumor with extracranial metastases and high, partially suppressible levels of adrenocorticotropin and related peptides.

Authors:  F E Kaiser; D N Orth; K Mukai; J H Oppenheimer
Journal:  J Clin Endocrinol Metab       Date:  1983-09       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.